Modified FOLFIRINOX in the treatment of pancreatic cancer – efficiency and toxicity

Vočka, Michal; Petruželka, Luboš

doi:10.14735/amgh2016413

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most patients’ performance status was 0 or 1, and a small portion had a score of 2 23 . Most of the studies removed the 5-FU bolus, but two studies reduced the dose from 400 mg/m 2 to 300 mg/m 2 27 , 29 . There was an overlap of population in one study 26 , 31 .…”

Section: Resultsmentioning

confidence: 99%

“…The most usage of continuous infusion 5-FU was 2400 mg/m 2 , but one study increased it to 2800 mg/m 2 or 3200 mg/m 2 and eliminated the 5-FU bolus 28 . The most frequently used dose of oxaliplatin was the same as the normal FOLFIRINOX regimen, but two studies used 63.75 mg/m 2 and 68 mg/m 2 29 , 31 . The dosage of irinotecan ranged from 135 mg/m 2 to 180 mg/m 2 .…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

The benefits of modified FOLFIRINOX for advanced pancreatic cancer and its induced adverse events: a systematic review and meta-analysis

Tong

Fan

Liu

et al. 2018

Sci Rep

View full text Add to dashboard Cite

FOLFIRINOX has been one of the first-line options for advanced pancreatic cancer, even though it induces significant adverse effects. Several institutions have begun using modified FOLFIRINOX to decrease its side effects and increase its tolerability. We systematically investigated the outcome from patients who initially received modified FOLFIRINOX as a chemotherapy regimen for advanced pancreatic cancer. We used the random-model generic inverse variance method to analyse the binary data with 95% confidence intervals (CIs). Eleven studies were included in the meta-analysis with 563 total patients. The 6-month and 1-year overall survival (OS) rates of locally advanced pancreatic cancer (LAPC) were 90.9% and 76.2%. The 6-month and 1-year progression-free survival (PFS) rates of LAPC were 81.5% and 48.5%. The 6-month and 1-year OS rates of metastatic pancreatic cancer (MPC) were 79.7% and 47.6%. The 6-month and 1-year PFS rates of MPC were 56.3% and 20.6%. The following rates were also calculated: complete response rate (CR): 2.9%; partial response rate (PR): 35.9%; stable disease rate (SD): 41.2%; overall response rate (OR): 34.6%; disease control rate (DCR): 76.7%; progressive disease: 23.1%; and grade III/IV adverse events (AEs): neutropenia 23.1%, febrile neutropenia 4.8%, thrombocytopenia 4.8%, anaemia 5.7%, fatigue 11.5%, nausea 9.1%, diarrhoea 10.1%, vomiting 5.7%, neuropathy 3.8%, and increased ALT 5.7%. In conclusion, modified FOLFIRINOX could provide comparative survival benefits with fewer adverse events compared to the conventional dosage.

show abstract